| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/20/2001 | CA2736957A1 Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders |
| 12/20/2001 | CA2412356A1 Immunosuppressor agent derived from morbillivirus |
| 12/20/2001 | CA2412343A1 Immunization through oral administration of a vaccine with an edible product |
| 12/20/2001 | CA2412257A1 Pro-apoptotic fragments of the dengue virus envelope glycoproteins |
| 12/20/2001 | CA2412223A1 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | CA2411967A1 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 12/20/2001 | CA2411965A1 The use of plant oil-bodies in vaccine delivery systems |
| 12/20/2001 | CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | CA2410604A1 Use of coiled-coil structural scaffold to generate structure-specific peptides |
| 12/20/2001 | CA2410532A1 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro |
| 12/20/2001 | CA2410229A1 Vaccine for congenital tremors in pigs |
| 12/20/2001 | CA2396871A1 Immunostimulatory nucleic acids for inducing a th2 immune response |
| 12/20/2001 | CA2351275A1 Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances |
| 12/19/2001 | EP1164375A2 Assay for anti transglutaminase antibodies |
| 12/19/2001 | EP1164196A1 Retroviral vectors |
| 12/19/2001 | EP1164188A1 Auxotrophic Mycobacterium mutants and tuberculosis vaccine |
| 12/19/2001 | EP1163909A2 Use of sugar ethers as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccine |
| 12/19/2001 | EP1163524A2 Methods of screening for colorectal cancer modulators |
| 12/19/2001 | EP1163522A1 Method for detecting superantigen activity in a biological sample |
| 12/19/2001 | EP1163516A1 Effect of brefeldin a on antigen-presenting cells |
| 12/19/2001 | EP1163343A2 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 12/19/2001 | EP1163342A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 12/19/2001 | EP1163335A1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION |
| 12/19/2001 | EP1163332A1 48 human secreted proteins |
| 12/19/2001 | EP1163331A1 50 human secreted proteins |
| 12/19/2001 | EP1163273A1 Method for the reductive animation of polysaccharides |
| 12/19/2001 | EP1163272A1 Antibodies specific for cyp1b1 |
| 12/19/2001 | EP1163271A1 Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders |
| 12/19/2001 | EP1163270A1 Dihydroouabain-like factor and diagnostic and therapeutic compositions and methods |
| 12/19/2001 | EP1163024A1 Delivery of macromolecules into cells |
| 12/19/2001 | EP1163008A1 Use of trehalose for stabilising a liquid vaccine |
| 12/19/2001 | EP1163003A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist |
| 12/19/2001 | EP1163002A2 Polycationic carbohydrates as immunostimulants in vaccines |
| 12/19/2001 | EP1163001A2 Vaccine composition |
| 12/19/2001 | EP1163000A2 Vaccine against antigens from bacteriae |
| 12/19/2001 | EP1162999A2 Vaccine against Streptococcus pneumoniae |
| 12/19/2001 | EP1162998A2 Vaccine against streptococcus pneumoniae capsular polysaccharides |
| 12/19/2001 | EP1162997A2 Staphylococcus antigen and vaccine |
| 12/19/2001 | EP1162996A2 Hapten-conjugated mammalian cells and methods of making and using thereof |
| 12/19/2001 | EP1162993A2 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 12/19/2001 | EP1162983A1 Vaccine for house dust mite allergen using naked plasmid dna |
| 12/19/2001 | EP1162950A1 Media in the form of complex dispersions, method for preparing same and uses |
| 12/19/2001 | EP1162945A1 Particle based vaccine composition |
| 12/19/2001 | EP1162880A1 Human sperm surface antigens |
| 12/19/2001 | EP0751785B2 Combinations of thrombolytically active proteins and anticoagulants, and uses thereof |
| 12/19/2001 | EP0666866B1 Method of isolating biomolecules by ion exchange |
| 12/19/2001 | EP0639080B1 Non-azo naphthalimide dyes and use as alkylating agents |
| 12/19/2001 | EP0623215B1 Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis |
| 12/19/2001 | EP0535021B1 Association between a human immunodeficiency virus-related retrovirus and sjogren's syndrome |
| 12/19/2001 | CN1327452A Fibroblast growth factor with hepatocyte proliferation activity |
| 12/19/2001 | CN1327388A Modified antibodies of induced anti-idiotype reaction enhancement |
| 12/19/2001 | CN1326939A Producing influenza killed vaccine by sepharose 4FF column chromatography technology |
| 12/19/2001 | CN1076204C Recombinant coccidiosis vaccines |
| 12/18/2001 | US6331616 Nucleotide sequences coding viral envelope protein; for use as diagnostic tool in detection of viral infection |
| 12/18/2001 | US6331615 Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand) |
| 12/18/2001 | US6331433 Human T cell leukemia cell line designated D1.1 |
| 12/18/2001 | US6331415 Methods of producing immunoglobulins, vectors and transformed host cells for use therein |
| 12/18/2001 | US6331411 TopA |
| 12/18/2001 | US6331410 Polynucleotides encoding a novel pyrR homolog |
| 12/18/2001 | US6331404 HIV envelope polypeptides |
| 12/18/2001 | US6331388 Preferential intensification of the expression of major histocompatbility complex particles; provide target cells, transform with expression vector, detect amplification major histocompatibility complex expression |
| 12/18/2001 | US6331304 Immunogenic composition comprising an attenuated form which is a strain of leishmania and which is transformed by a plasmid containing the gm-csf gene |
| 12/18/2001 | US6331303 LKTA deletion mutant of P. haemolytica |
| 12/18/2001 | US6331301 Isolated dna sequences which encodes amino acid sequence in protein; |
| 12/18/2001 | US6331299 Method for treatment of cancer and infectious disease and compositions useful in same |
| 12/18/2001 | US6331298 Wound healing and treatment of fibrotic disorders |
| 12/18/2001 | US6331175 Method and kit for imaging and treating organs and tissues |
| 12/18/2001 | CA2224052C Pertussis outer membrane protein |
| 12/13/2001 | WO2001094949A2 Soluble cd1 compositions and uses thereof |
| 12/13/2001 | WO2001094944A2 Artificial antigen presenting cells and methods of use thereof |
| 12/13/2001 | WO2001094631A1 Methods for detection of cryptosporidium species and isolates and for diagnosis of cryptosporidiuminfections |
| 12/13/2001 | WO2001094599A1 Gene expression cassette and its use |
| 12/13/2001 | WO2001094597A1 Purified proenzyme of dipeptidyl peptidase i (pro-dppi) |
| 12/13/2001 | WO2001094587A2 Extracellular messengers |
| 12/13/2001 | WO2001094586A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 12/13/2001 | WO2001094585A1 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
| 12/13/2001 | WO2001094553A1 Method of amplifying natural killer t cells |
| 12/13/2001 | WO2001094551A2 Genetically modified t-cells, method for producing them and use thereof |
| 12/13/2001 | WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | WO2001094419A2 Method to induce the th1 immune response |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094387A2 Epididymis-specific proteins with fibronectin type ii modules |
| 12/13/2001 | WO2001093913A2 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | WO2001093912A1 Vaccine |
| 12/13/2001 | WO2001093906A1 Adjuvant composition comprising fha protein or fragment of fha protein in free form |
| 12/13/2001 | WO2001093905A1 Immunostimulatory oligodeoxynucleotides |
| 12/13/2001 | WO2001093903A1 Antigenic composition comprising a polycationic peptide and inosine and cytosine |
| 12/13/2001 | WO2001093902A2 Immunostimulatory rna/dna hybrid molecules |
| 12/13/2001 | WO2001093901A1 Combined preparation for the treatment of neoplasic diseases |
| 12/13/2001 | WO2001093900A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 12/13/2001 | WO2001093898A1 Methods of treating viral diseases with il-18 and il-18 combinations |
| 12/13/2001 | WO2001093893A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 12/13/2001 | WO2001093835A1 Delivery systems for bioactive agents |
| 12/13/2001 | WO2001093829A2 Powder compositions |
| 12/13/2001 | WO2001093804A2 Hepatitis c virus conjugates |
| 12/13/2001 | WO2001051603A3 Pharmaceutical composition and method of using the same |
| 12/13/2001 | WO2001046408A3 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 12/13/2001 | WO2001045735A3 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001040269A3 Compositions and methods for therapy and diagnosis of breast cancer |